Regeneron Pharmaceuticals Inc (LTS:0R2M)
$ 676.38 +3.995 (+0.59%) Market Cap: 70.47 Bil Enterprise Value: 64.42 Bil PE Ratio: 16.38 PB Ratio: 2.25 GF Score: 87/100

Regeneron Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript

May 12, 2026 / 05:00PM GMT
Release Date Price: $720.16 (-0.19%)
Tazeen Ahmad
Bofa Merrill Lynch Asset Holdings Inc - Analyst

Thank you for joining us. Welcome back to the Bank of America Global Healthcare Conference. It's my pleasure to have with me our next presenting company, Regeneron Pharmaceuticals, Inc. Up here on stage with me are two members that we'll be talking to for the next 30 minutes, Marion McCourt, who is, of course, Executive Vice President, Commercial, as well as Ryan Crowe, who is Senior Vice President, Investor Relations. Guys, thanks for making the trip over from the East Coast to (technical difficulty)

Questions & Answers

Ryan Crowe
Regeneron Pharmaceuticals Inc - Senior Vice President, Investor Relations & Strategic Analysis

In exchange, we are not going to be subject to future government pricing mandates, and we'll also have tariff relief through at least January of 2029.

So, all in all, a very similar construct to the previous deals that were announced. Perhaps one detail that we've included in some of our disclosures is that this includes products that are wholly owned by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot